In-House vs Outsourced Regulatory Affairs: A Build/Buy Framework

As a life sciences company grows, regulatory affairs shifts from an occasional need to a structural one, and the question of how to resource it becomes recurring. Should the next increment of regulatory capability be built internally or sourced from external providers? The decision is rarely all-or-nothing. Most companies operate a mix, and the useful question is which specific regulatory work belongs inside and which is better sourced externally, under what oversight.

This guide sets out a framework for that build/buy decision, framed around the variables that actually drive it rather than a blanket preference for either model. It also addresses the principle that constrains the whole decision: outsourcing execution does not outsource accountability.

The external option is substantial and growing, which is part of why the build/buy question is now recurring rather than occasional. Market estimates vary by methodology and should be treated as directional rather than precise: IMARC puts the regulatory affairs outsourcing market at roughly USD 8.9 billion in 2025, while Grand View Research projects high-single-digit annual growth through 2030 (IMARC; Grand View Research). The figures differ, but the direction is consistent: outsourced regulatory capacity is widely available, so the question is less whether external help exists than which work it should do.

The decision is per-activity, not per-company

The first correction to make is to stop treating “in-house vs outsource” as a single company-level choice. Regulatory affairs is not one homogeneous function. It spans strategic judgment, specialist expertise, local market coverage, high-volume operational work, and execution-oriented support, and these have different answers.

A useful split is between work requiring senior regulatory judgment and execution-heavy work. Judgment-heavy work includes pathway selection, agency strategy, evidence interpretation, and regulatory risk framing. Execution-heavy work includes process-driven activities such as publishing, submission assembly, country maintenance, and tracking. Within each category, the build/buy answer depends on how continuous, predictable, and specialized the work is. A company might sensibly build internal strategic leadership while outsourcing publishing, or build internal operations while sourcing specialized strategic advice for a particular product class, market, or authority interaction.

The practical question becomes: for this activity, at this stage of the company, is internal capability or external sourcing the better fit? Asking it activity by activity produces a far better resourcing model than a single blanket policy.

Variables that favor building in-house

Several factors point toward internal capability.

Continuity and frequency. Work that is constant and ongoing is often more efficient and better controlled in-house. If a capability is needed every week, paying for it continuously internally can be both cheaper and more aligned than repeatedly sourcing it. Recurring work also builds internal expertise that compounds over time.

Strategic centrality and control. Core regulatory strategy, institutional knowledge, and decisions that define the company’s regulatory posture benefit from internal ownership. These are hard to delegate without losing control of the company’s direction, and they are precisely the areas where a company most needs its own informed judgment.

Accountability and oversight capacity. Even fully outsourced work requires internal oversight. A company needs enough internal capability to challenge weak external advice, manage providers, and own submitted content. Building at least a core of internal judgment is often a prerequisite for outsourcing the rest safely, because a company that cannot evaluate the advice it receives is poorly placed to rely on it.

Institutional memory. Knowledge that compounds over time, such as product history, prior authority interactions, and internal decisions, is more durable when held internally. Relying entirely on external providers for this knowledge creates a dependency that is risky if the relationship ends.

Variables that favor outsourcing

Other factors point toward external sourcing.

Specialization beyond what is worth hiring. Some expertise is too specialized or too occasional to justify a full-time hire, such as a specific device class, a niche pathway, or a particular authority interaction. Sourcing this when needed is often more sensible than building it, and gives access to depth that a generalist internal team could not match.

Spikes and variability. Submission waves, audits, remediations, and market-entry pushes create demand that exceeds steady-state capacity. Outsourcing absorbs peaks without permanently expanding headcount, which would then be underused once the peak passes.

Speed when a deadline depends on capacity. When timing is critical and internal capacity is unavailable, external providers can add capability faster than hiring, which is often slow for specialized regulatory roles.

Geographic and country-specific coverage. Local representation and country-specific requirements are often better met through external local expertise than through building presence in every market. Building local capability in every jurisdiction a company touches is rarely justified.

Early-stage absence of internal leadership. Smaller companies may lack internal regulatory leadership entirely. Here, outsourcing, often including fractional or interim leadership, may be the only realistic near-term option, though it raises the importance of provider selection because there is less internal capability to challenge weak advice.

A simple framework

Most scaling companies land on a hybrid: an internal core that owns strategy, oversight, and continuous work, supplemented by external providers for specialized, variable, or peak demand. The mix shifts as the company grows, typically building internal capability as a need becomes continuous enough to justify it.

Common hybrid models

The right model depends on the company’s stage, product complexity, markets, and volume of regulatory work. A few patterns recur.

Internal regulatory lead plus outsourced execution. This works when the company needs internal ownership of strategy, decisions, and authority interactions, but external capacity for publishing, submission assembly, country maintenance, document production, or tracking. The internal lead owns the regulatory position; external providers add execution capacity.

Fractional or interim regulatory leadership plus specialist providers. This often fits early-stage companies that are not ready for a full-time regulatory head but still need senior judgment. A fractional or interim leader can help define the regulatory plan, supervise providers, and decide when a permanent internal role becomes justified.

Internal operations plus outsourced specialist advice. This works when the company has a functioning regulatory team but needs niche expertise for a specific market, authority interaction, device class, CMC issue, clinical evidence question, or remediation project. The internal team keeps continuity; the external provider supplies depth.

Internal global core plus local market partners. This suits companies entering multiple countries where local requirements, language, representation, or submission practices matter. The internal team owns global strategy and standards, while local providers handle country-specific execution and interpretation.

The common thread is that hybrid models work best when roles are explicit. Internal teams should know what they own, external providers should know what they are being asked to deliver, and the company should retain enough internal capability to supervise, challenge, and integrate the work.

The hidden costs on both sides

The build/buy comparison is often made on visible cost alone, which distorts it. Both models carry less visible costs that belong in the decision.

Building in-house carries the full cost of employment, including recruitment, salary, benefits, management, training, and the risk of carrying capacity through quiet periods. It also carries the time and risk of hiring, which is significant for specialized regulatory roles, and the opportunity cost of a mis-hire.

Outsourcing carries the cost of oversight, which is real even when the work is delegated, along with the cost of bringing providers up to context, the risk of dependency on an external relationship, and a per-unit cost that is usually higher than internal delivery for continuous work. A model that looks cheap because it avoids headcount may be expensive once oversight and context-transfer are counted.

A sound decision counts both the visible and the hidden costs on each side, for the specific activity in question, rather than comparing a salary to an invoice.

Outsourcing does not outsource accountability

Whichever way the decision goes, one principle holds. External providers can perform substantial regulatory work, but they do not generally replace the sponsor’s, applicant’s, manufacturer’s, or marketing authorisation holder’s responsibility for regulatory decisions, oversight, and content submitted under the company’s name. For clinical trials, ICH E6(R3), finalized in January 2025, permits transfer of trial-related activities to service providers, but responsibility for the conduct of the trial remains with the sponsor, along with the expectation of documented agreements and active oversight.

This means even a heavily outsourced model still requires enough internal capability to supervise, challenge, and own the work. It also argues for building at least a core of internal judgment in companies that outsource heavily. The cost of that oversight capacity is part of the true cost of outsourcing, and a company that omits it is not saving money so much as carrying unmanaged risk.

Revisiting the decision as you scale

The build/buy balance is not set once. A capability that is best outsourced at one stage may become continuous enough to bring in-house at the next, and a function built internally may be better supplemented externally during a spike. Treat the decision as a periodic review tied to how the company’s regulatory demand is actually evolving, not a one-time commitment.

A practical rhythm is to revisit the mix whenever the company’s regulatory demand changes materially, such as entering new markets, advancing a programme to a new stage, or facing a sustained increase in volume. Each of these can shift an activity across the build/buy line, and recognizing that early avoids both under-resourcing and carrying capacity that is no longer needed.

When you outsource, source it confidentially

When the build/buy decision points to outsourcing, RegSeek gives you a confidential way to do it. If you already know the work you need external providers to perform, you can post the need as a confidential request for proposal (RFP) with company identity masked, receive comparable expressions of interest (EOIs) from vetted regulatory providers, and shortlist on fit. You pay to unlock selected providers through Shortlist & Connect only when you are ready to reveal identities and contact them directly.

If the need is complex, confidential, multi-market, or not yet clearly scoped, RegSeek-Assisted Sourcing can help refine the brief, define the right provider profile, run confidential outreach, and support shortlist comparison. That is useful when the question is not just “who can do this work?” but also “how should this work be packaged before we approach the market?”

For a focused question rather than a full outsourcing project, Written Regulatory Advice gives you a written answer from a matched regulatory advisor. In each case, the clearer the activity, deliverable, and oversight model, the better the external response will be.

FAQ

Should an early-stage company build a regulatory team or outsource?

Early-stage companies often outsource out of necessity, sometimes including fractional or interim leadership, because the demand does not yet justify full-time hires. As regulatory demand becomes continuous, building an internal core, starting with senior judgment and oversight, usually follows.

What should never be fully outsourced?

Accountability and oversight. Final decisions, final ownership of submitted content, and the capacity to challenge external advice should remain internal, even when execution is outsourced. Core strategy and institutional knowledge also benefit from internal ownership.

Is outsourcing cheaper than hiring?

It depends on frequency, and on counting the hidden costs. For occasional or specialized work, outsourcing is usually cheaper than a full-time hire; for continuous work, internal capability is often both cheaper and better controlled once oversight and context-transfer costs are included. The comparison should be made per activity, not for regulatory affairs as a whole.

How do we decide when to bring an outsourced function in-house?

Watch for an activity becoming continuous, central, and predictable enough that paying for it internally would be both cheaper and better controlled. A recurring spend on the same outsourced work, and a growing need to control it closely, are signals that it may have crossed the line toward an internal hire.

Sources and Further Reading

• ICH, E6(R3) Good Clinical Practice Guideline (on sponsor responsibility and oversight when activities are transferred).
• IMARC, Regulatory Affairs Outsourcing Market; Grand View Research, Regulatory Affairs Outsourcing Market Size & Outlook (market estimates, treated as directional).
• RegSeek, Regulatory Affairs Outsourcing in Life Sciences (on why companies outsource and matching providers to the work).
• RegSeek, Regulatory Affairs Scope of Work Template (on turning an outsourced need into a clear provider brief).

Need help with a similar regulatory sourcing decision? Submit a confidential brief →

← All resources